BioWorld Asia

Aug. 9, 2006

Paion Accelerates Phase III Program For Desmoteplase

Paion AG is accelerating the Phase III development program for its lead compound, the recombinant plasminogen activator Desmoteplase, which is in development for treating acute ischemic stroke. (BioWorld International) Read More

Serum Institute Invests In Lipoxen; Firms Sign Deal

Neutralizing Antibody Has Promise Versus HIV Strains

Biosecurity Rises Higher Up On Europe's Agenda

Chasing Next-Generation Stents, Axordia Working With Lombard

After Knocking Out Genes, Rye Grass Pollen Made Sneeze-Free

Immutep Initiating Phase I IMP321 Breast Cancer Trial

Diamyd Medical Enters First GAD65 Out-Licensing Deal

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 29, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...

GT-02897 exerts efficacy in preclinical multiple myeloma

BioWorld Science

Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...